Cue Biopharma Announces Positive Topline Results From Cue-221 Phase 2 Study In Chronic Spontaneous Urticaria
CUE•Cue Biopharma reports positive Phase 2 topline results
Sept. 20 (Reuters) - Cue Biopharma, Inc. CUE.O:
- Cue Biopharma announces positive topline results from Cue-221 Phase 2 study in chronic spontaneous urticaria
- Cue Biopharma says Phase 2 primary and key secondary endpoints were met
Source text: ID:nGNXYm9rX
Further company coverage: CUE.O
